基本信息
浏览量:184
职业迁徙
个人简介
His research focuses on molecularly-targeted therapeutics for acute leukemia. His principal expertise is in FLT3 inhibitors for AML and he has played a leading role in clinical trails of these agents. He also studies other agents targeting signal transduction, such as tyrosine kinase inhibitors for Ph-like ALL and inhibitors of oncogenic PI3K/AKT/mTOR signaling. His laboratory studies focus on phospho-specific flow cytometry of fixed, unfractionated blood and marrow as a method to quantify pharmacodynamic response to signal transduction inhibitors. He is additionally interested in preclinical drug screening in cellular and murine xenotransplantation models of acute leukemia.
研究兴趣
论文共 216 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Transplantation and cellular therapyno. 4 (2023): 265.e1-265.e10
TRANSPLANTATION AND CELLULAR THERAPYno. 4 (2023): 265-274
TRANSPLANTATION AND CELLULAR THERAPYno. 4 (2023)
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023): S521-S522
American journal of hematologyno. 8 (2023): 1254-1264
引用0浏览0WOS引用
0
0
Mark J. Levis,Harry P. Erba,Pau Montesinos,Radovan Vrhovac,Elzbieta Patkowska,Hee-Je Kim,Pavel Zak,Po-Nan Wang, Jaime E. Connolly Rohrbach,Ken C. N. Chang,James Hanyok, Li Liu,
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023): S272-S272
引用0浏览0引用
0
0
Cheryl A C Peretz,Vanessa E Kennedy,Anushka Walia,Cyrille L Delley,Andrew Koh,Elaine Tran,Iain C Clark, Corey E Hayford, Chris D'Amato,Yi Xue,Kristina M Fontanez,Ritu Roy,
bioRxiv : the preprint server for biology (2023)
引用1浏览0WOS引用
1
0
Cancersno. 21 (2023): 5129-5129
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn